Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2008

01-08-2008 | Correspondence

Acetylcholinesterase Inhibitors May Improve Efficacy and Reduce Adverse Effects of Tricyclic Antidepressants for Depression

Author: Helmut Niederhofer

Published in: Drugs & Aging | Issue 8/2008

Login to get access

Excerpt

Passmore et al.[1] report that acetylcholinesterase inhibitors, antiepileptics, lithium, anxiolytics, analgesics, β-adrenoceptor antagonists, cannabinoid receptor agonists and hormonal agents may be effective in treating dementia-related agitation. Figiel and Sadowski[2] report that the cholinergic system appears to be involved in different behaviours and disorders, including depression. Acetylcholinesterase inhibitors have been developed for the treatment of dementia, in which setting they enhance acetylcholine levels and have neuroprotective functions.[3] …
Literature
1.
Passmore MJ, Gardner DM, Polak Y, et al. Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs Aging 2008; 25(5): 381–98PubMedCrossRef
2.
Figiel G, Sadowski C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioural disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008; 24: 157–66PubMedCrossRef
3.
Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer’s disease: an update. Clin Interv Aging 2007; 2: 17–32PubMedCrossRef
4.
Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci 2001; 931: 1–16PubMedCrossRef
5.
Cancelli I, Marcon G, Balestieri M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol 2004; 19(8): 577–84PubMedCrossRef
6.
Hay F, Linkowski P. Antidepressants: TCA versus SSRI versus other new agents [in French]. Rev Med Brux 2004; 25(4): A315–20PubMed
7.
Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36PubMedCrossRef
Metadata
Title
Acetylcholinesterase Inhibitors May Improve Efficacy and Reduce Adverse Effects of Tricyclic Antidepressants for Depression
Author
Helmut Niederhofer
Publication date
01-08-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825080-00008

Other articles of this Issue 8/2008

Drugs & Aging 8/2008 Go to the issue

Original Research Article

What Factors Predict Potentially Inappropriate Primary Care Prescribing in Older People?

Review Article

Pathophysiology and Treatment of Psychosis in Parkinson’s Disease

Review Article

Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction

Leading Article

Role of Methotrexate in the Treatment of Bullous Pemphigoid in the Elderly

Original Research Article

Exposure to Potentially Inappropriate Drugs and Drug-Drug Interactions in Elderly Nursing Home Residents in Helsinki, Finland

Original Research Article

Defining Treatment Response to Donepezil in Alzheimer’s Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits